While all three referees acknowledge that the findings are potentially interesting, they all point out that significant revisions are required and that the functional link between USP26 and the TGF receptor and TGF/Smad signaling need to be strengthened before the study can be considered for publication here. The referees raise concerns about the fact that overexpressed proteins are used throughout the study and upon further discussion with the referees all agree that protein stability should be measured in stable cell lines, although these need not to be tumor cell lines. The referees are also concerned that no evidence is provided that USP26 controls endogenous Smad7 and TbRI.
Thank you for the submission of your research manuscript to EMBO reports and for your patience while the manuscript was under review. We have now received the full set of referee reports that is copied below.
While all three referees acknowledge that the findings are potentially interesting, they all point out that significant revisions are required and that the functional link between USP26 and the TGF receptor and TGF/Smad signaling need to be strengthened before the study can be considered for publication here. The referees raise concerns about the fact that overexpressed proteins are used throughout the study and upon further discussion with the referees all agree that protein stability should be measured in stable cell lines, although these need not to be tumor cell lines. The referees are also concerned that no evidence is provided that USP26 controls endogenous Smad7 and TbRI.
Upon further discussion with referee 2 s/he also specified the more general comments listed as major points 3 and 4 in more detail and suggests the following experiments:
Point#3: The authors should genetically disrupt the expression of USP26 by shRNA in the glioblastoma cells and then check the ubiquitination status as well as protein stability of SMAD7. The utilization of USP26 inhibitors to address this point is encouraged but not obligated.
Point#4: The authors should check the activity of downstream effectors in the TGF pathways in control cells and USP26-depleted cells in response to TGF stimulation. It would help to understand the role of USP26 in TGF pathway in general.
From these comments it is clear that publication of the manuscript in our journal cannot be considered at this stage. On the other hand, given the potential interest of your findings, I would like to give you the opportunity to address the concerns and would be willing to consider a revised manuscript with the understanding that the referee concerns must be fully addressed and their suggestions taken on board. Should you decide to embark on such a revision, acceptance of the manuscript will depend on a positive outcome of a second round of review. It is EMBO reports policy to allow a single round of revision only and acceptance or rejection of the manuscript will therefore depend on the completeness of your responses included in the next, final version of the manuscript.
Revised manuscripts should be submitted within three months of a request for revision; they will otherwise be treated as new submissions. Please contact me if a 3-months time frame is not sufficient for the revisions so that we can discuss the revisions further and extend this deadline, 4 months might be more realistic.
--------------------------------REFEREE REPORTS

Referee #1:
In this manuscript, the authors reveal that USP26, a deubiquitinating enzyme, participates in a negative feedback loop to modulate TGF-signaling by deubiquitinating and stabilizing SMAD7. Mechanistically, USP26 acts as a SMAD7 ubiquitin chain specific deubiquitylase to protect SMAD7 from proteosome-mediated degradation pathway. This then facilitates SMAD7-SMURF2 conjunction promoting TGF-receptor complex degradation and leading to reduced TGF-activity. Moreover, knockdown of USP26 enhanced TGF-induced migration in tumor cells. Overall, the authors identified USP26 as part of a negative feedback loop regulator of the TGF-pathway. There are some concerns that need to be addressed.
Major concerns:
1. The authors claim that USP26 is selected by a shRNA deubiquitinating enzyme screen, and they finally confirm that knockdown of USP26 greatly enhanced TGF-activity ( Figure 1A and 1C). To draw this conclusion more compelling, one or two excluded DUB(s) should be employed as a negative control in Figure 1A .
2. In Figure 1B , the authors show inhibitory effect of shRNA vectors on USP26 by using GFP antibody to measure the exogenous GFP-USP26 fusion protein expression, for the reason that they failed to find appropriate antibody detecting endogenous USP26 in Western blotting assay. To verify endogenous USP26 is inhibited by the corresponding shRNAs, mRNA of endogenous USP26 should be measured without GFP-USP26 overexpression conditions. 3. It shows that USP26 knockdown apparently enhanced TGF-induced migration and invasion (Sup. Figure 8A-D) . On the other hand, the authors should confirm whether overexpression of USP26 has an inhibitory effect on TGF-induced migration.
4. IHC staining of tumor samples with high p-SMAD2 level and low USP26 expression should be presented compared to that of existing tumor sections in Figure 4B . Figure 4D , the authors should provide further evidence to show that SMURF2 accelerates SMAD7 ubiquitination and degradation in USP26 knockdown cells.
To support the working model shown in
Minor comments:
1. Endogenous SMAD7 should be presented by anti-SMAD7 antibody in Figure 3C , 3D and Sup. Figure 5A , 5B. Figure 3C and 3D, the authors should explain why the "Flag signaling" is positive in the first column where the control vector, but not flag-SMAD7, is transfected into 293T cells.
In
3. Proteasome inhibitor MG132 is used to block ubiquitination-mediated protein degradation, which helps to determine the different levels of ubiquitinated protein between each group in IP assays. Therefore, this critical condition should be indicated in Figure 3A , 3H and Sup. Figure 2A , 2B.
Referee #2:
In this manuscript, Lui et al. reported USP26 as a key component of the TGF negative feedback loop by deubiquitinating the T R inhibitor SMAD7. They found that knock-down of USP26 upregulated the TGF signaling, which was mediated by increased phosphorylation of SMAD2. Consistently, overexpression of USP26 inhibited TGF signaling and suppressed SMAD2 phosphorylation. By a systematic analysis of the affinity of USP26 to 7 SMADs, they found that USP26 interacted with SMAD7. They revealed that knock-down of USP26 increased the ubiquitination of SMAD7, leading to decreased SMAD7 proteins. However, knock-down of USP26 decreased the ubiquitination of T RI, which is regulated by SMAD7. Therefore, they concluded that USP26 deubiquitinates SMAD7, which in turn upregulates ubiquitination and degradation of T RI. Finally, they showed that in glioblastoma tissues, USP26 signal inversely correlated with pSMAD2 signal. In addition, high USP26 expression favors GBM patient prognosis, suggesting some clinical significance of USP26. The regulation of the TGF pathway through the DUB mediated stability of the key component in the TGF negative feedback loop is an interesting point. Whereas the logic is attractive, more data are required to make the conclusion solid. Furthermore, the importance of the USP26 on the whole TGF pathway signaling should be clarified.
1. The authors tended to use overexpression in 293FT cells throughout the manuscript to address the biochemical mechanisms. Although it is okay to determine the interactions between proteins, it is vague to determine the stability of the proteins affected by ubiquitination. The overexpressing efficiency itself may affect the protein levels. Since the authors mentioned in the manuscript that they had established some stable cell lines, they may want to address the protein stability issue by using these stable cell lines. 2. The authors used a lot of qPCR assays to determine the effect of USP26. However, USP26 is a DUB that functions on the post-translational level. The authors may want to show the protein levels to clarify the function of USP26. 3. The ubiquitination assays lacked some critical experiments. 4. Whereas the effect of USP26 on SMAD7 was clearly demonstrated, the effect of USP26 on the TGF pathway in general was not that clear.
Other concerns: 1. The authors showed that USP26 mRNA was upregulated after TGF treatment. They may want to determine the protein levels of USP26 before and after TGF treatment in tumor cells. 2. The upregulation of SMAD7 proteins by knock-down of USP26 was only determined in 293FT overexpressing system. It should be determined in tumor cells by detection of the endogenous SMAD7 proteins. 3. The authors used a reporter system to show the upregulation of TGF signaling by knock-down of USP26. They should provide some evidence of the activation of TGF pathway in tumor cells by checking the downstream targets of TGF pathway. 4. Since the authors used overexpression of USP26 in 293FT cells in a lot of experiments, they may want to present the endogenous and ectopic USP26 protein levels side by side. 5. Fig 2D, given that the input of USP26 is much less in the pull-down assay of SMAD3, it is possible that SMAD3 had the similar affinity to USP26. The authors may want to clarify it. 6. Fig 3 C, D , F, and G used overexpression of multiple plasmid to address the stability of a certain protein, which is questionable. It would be better to determine the stability of the endogenous target proteins either in the stable cell lines or in tumor cell lines. 7. Fig 3E the actin input was not even, which made the trend of SMAD7 proteins questionable. It is also strange that the TGF stimulation was applied in this assay. Fig 3A and B showed a strong UB signal without TGF , suggesting that TGF stimulation is not required to trigger the degradation of SMAD7. 8. Whereas USP26 knock-down upregulated the ubiquitination of SMAD7, overexpression of USP26 as a DUB to downregulate the ubiquitination of SMAD7 should be presented. 9 . Fig 1D showed that KD of USP26 dramatically upregulated SMAD7 mRNA levels. Is it possible that in tumor cells, lack of USP26 may trigger the upregulation of SMAD7 transcription to compensate for the loss of SMAD7 proteins? The authors may want to do the immunohistochemical analysis of the tumor tissues used in Fig 4 to address the question. 10. Could the authors perform a combined analysis of TGF and USP26 by using the REMBRANDT database to clarify the importance of USP26 in TGF pathway? They could compare the patient prognosis of TGF High/LowUSP26High/Low groups (4 groups).
Referee #3:
The authors report that the de-ubiquitylase USP26 controls the stability of the inhibitory Smad7, which is known to bring Smurf2 (and perhaps some other E3 ubiquitin ligases) to the type I TGF-b receptor (TbRI) and thus promotes TbRI degradation. Consequently, USP26 is seen as a determinant of TGF-b signaling. The authors also correlate loss of USP26 with high TGF-b activity and poor prognosis in glioblastomas.
Overall, the authors show some interesting results that highlight the potential role of USP26 as a deubiquitylase for Smad7 that controls TGF-b signaling. This report adds to previous reports on other de-ubiquitylases that control TGF-b signaling. The data shown are convincing. Where I have a problem is that overall this story is not very well worked out. Specifically, I am missing convincing evidence that (1) USP26 controls Smad7 and TbRI stability at endogenous levels of these signaling mediators, (2) that USP26 is functionally linked to ubiquitylation of TbRI by Smurf2. These aspects should be better worked, realizing very well that these experiments are harder than those shown. Responses to reviewer's comments:
We thank the reviewers for the thoughtful and thorough revision of the manuscript. Thanks to their insights and comments our manuscript has greatly improved. We are glad to report that we have addressed the majority of the concerns and comments raised by the reviewers. We have now 27 new figure panels (Figs. 1C, 2E, 2F, 3C, 3D, 3E, 3H, 3I, 4E, 4F, 4G , 5B, 5C, EV1A, EV1B, EV1C, EV1G, EV2A, EV2B, EV2C, EV2D, EV2G, EV3E, EV5B, EV5C, EV5D, EV5E).
Reviewer #1:
The authors claim that USP26 is selected by an shRNA deubiquitinating enzyme screen, and finally confirm that knockdown of USP26 greatly enhanced TGF-β activity ( Figure 1A and 1C). To draw this conclusion more compelling, one or two excluded DUB(s) should be employed as a negative control in Figure 1A .
We thank the reviewer for their critical reading of the manuscript. We have provided the original screen and corresponding table demonstrating the individual DUB activity on the CAGA-Luc reporter. This experiment demonstrates the enhanced luciferase activity of DUB51 pool (USP26).
(New figure EV1A , B)
Reviewer #1: In Figure 1B We thank the reviewer for bringing up this point. We now demonstrate knockdown of endogenous USP26 by hairpins shUSP26-1 shUSP26-2. (New figure 1C)
Reviewer #1: It shows that USP26 knockdown apparently enhanced TGF-β induced migration and invasion (Sup. Figure 8A-D). On the other hand, the authors should confirm whether overexpression of USP26 has an inhibitory effect on TGF-β induced migration.
Following the reviewers suggestion we generated MDA-MB-231 cells ectopically expressing GFP-USP26 or its corresponding GFP-USP26 DD mutant. We show that overexpression of USP26 decreased the invasion capacity of MDA-MB-231 cells following exposure to TGF-β. An effect which was diluted in USP26 mutant cell line. (New figure 4E, F, G). Figure 4B .
Reviewer #1: IHC staining of tumor samples with high p-SMAD2 level and low USP26 expression should be presented compared to that of existing tumor sections in
We agree with the referee and we thank him for raising this point. We have now included a patient sample, which more adequately demonstrates low USP26 and corresponding high pSMAD2. Figure 4D , the authors should provide further evidence to show that SMURF2 accelerates SMAD7 ubiquitination and degradation in USP26 knockdown cells.
We would like to thank the reviewer for bringing up this issue as it gives us the opportunity to discuss this point in detail and apologise for any lack of clarity within our discussion. We had originally stated in the discussion, "As SMURF2 does not directly target SMAD7 for ubiquitination […] We would like to address the following question from Reviewer number 3 along with the question above.
Reviewer #3: Related to the functional link of USP26 with Smurf2-mediated ubiquitylation, what is the effect of increased or decreased USP26 expression on Smad7 levels when Smurf2 expression is downregulated?
In respect to the suggestions above we do not believe that USP26 counteracts the ubiquitination of SMAD7 by SMURF2 as SMURF2 is Lys63 ligase while USP26 is Lys48 deubiquitinase. Nevertheless, we performed the experiments as suggested by both reviewers. To our surprise knockdown of SMURF2 decreased SMAD7 expression, which was further decreased by knockdown of USP26. As this was completely unexpected we performed this experiment in three independent cell lines stably knocked down for USP26 and observed similar results. We also observed this result in SMURF2 CRISPR knockout cell lines.
[Data not included in peer review process file.] Therefore, in the answer to the reviewer's questions we do not believe that SMURF2 accelerates SMAD7 ubiquitination or degradation in USP26 knockdown cells. But rather, through the reviewer's suggestions we have now described a completely unexpected novel mechanism for SMAD7 stability whereby SMURF2/SMAD7 complex formation somehow appears to stabilize SMAD7. The details of this mechanism will be explored in future studies. With the reviewer's permission we would like to exclude this data from this manuscript as it does not add to our original argument that USP26 acts as a Lys48 deubiquitinase counteracting the function of a E3 ligase, not SMURF2, resulting in the stability of SMAD7. We have also revised the discussion section to include these points in greater detail.
Reviewer #1: Endogenous SMAD7 should be presented by anti-SMAD7 antibody in Figure 3C , 3D and Sup. Figure 5A , 5B.
We agree with the reviewer. We now demonstrate that knockdown of USP26 decreases endogenous SMAD7 levels. (New Figure 3C, 3E ).
Reviewer #1: In Figure 3C and 3D, the authors should explain why the "Flag signaling" is positive in the first column where the control vector, but not flag-SMAD7, is transfected into 293T cells.
We regret the lack of clarity in our figures. We consistently observe a background band at 46 kDa when using FLAG rabbit antibodies. This has now been denoted in the respective figures. (Fig. 3A,  B. Fig. EV3E,F Figure 3A , 3H and Sup. We thank the reviewer for pointing out our omission. We have now included this detail where appropriate. We thank the reviewer for their time in reading this manuscript. We now demonstrate that loss of USP26 degrades endogenous SMAD7 and stabilizes endogenous TGF-β receptor I (New Figure 3C, We thank the reviewer for their suggestion. Unfortunately, we were unable to identify an antibody that effectively detected endogenous USP26 by western blot.
Reviewer #2: The authors should genetically disrupt the expression of USP26 by shRNA in the glioblastoma cells and then check the ubiquitination status as well as protein stability of SMAD7. The utilization of USP26 inhibitors to address this point is encouraged but not obligated.
We like to thank the reviewer for this excellent suggestion. For the reviewers information we analyzed endogeous ubiquitination levels of endogenous SMAD7 in the glioblastoma primary cultured human cell line and observed that in cells depleted for USP26 the levels of incorporated ubiquitin on SMAD7 increased. These results are in line with our previous results in 293T cells.
[Data not included in peer review process file.]
Reviewer #2: The authors should check the activity of downstream effectors in the TGFβ pathways in control cells and USP26-depleted cells in response to TGFβ stimulation. It would help to understand the role of USP26 in TGFβ pathway in general.
We thank the reviewer for raising this point. This is an important issue that we have now addressed. We had previously shown that loss of USP26 degrades SMAD7, therefore leading to stabilization of the TGF-β receptor as in the absence of SMAD7 SMURF2 can no longer be recruited to the TGF-β receptor complex to ubiquitinate it. The resulting stabilization of the TGF-β receptor enhances TGF-β activity as evidenced by increased phosphorylation of the SMAD transcription factor SMAD2. We now demonstrate that USP26 also plays a role on SMAD3 activity. Furthermore, we demonstrate that the enhanced activation of these transcription factors leads to an overall enhanced TGF-β transcriptional output as we observed increased transcription of TGF-β target genes, p21, PAI1, CTGF, and LIF. We thank the reviewer for highlighting this important point. Unfortunately, we were not able to identify an antibody that was capable of detecting endogenous levels of USP26.
Reviewer #2: The upregulation of SMAD7 proteins by knock-down of USP26 was only determined in 293FT overexpressing system. It should be determined in tumor cells by detection of the endogenous SMAD7 proteins.
We understand that the reviewer meant " The downregulation of SMAD7 proteins by knock-down of USP26 was only determined in 293FT overexpressing system. " We have now demonstrated that knockdown of USP26 diminishes endogenous SMAD7 levels. (New figure 3C, E) .
Reviewer #2: The authors used a reporter system to show the upregulation of TGFβ signaling by knock-down of USP26. They should provide some evidence of the activation of TGFβ pathway in tumor cells by checking the downstream targets of TGFβ pathway.
We agree and we have now demonstrated that loss of USP26 enhances the transcription of the TGF-β target genes SMAD7, CTGF, and LIF to go along with our previous data on SMAD7. (New Figure EV3 E We agree. However, as mentioned we were unable to identify an antibody that was able to detect endogenous levels.
Reviewer #2: Fig 2D, given that the input of USP26 is much less in the pull-down assay of SMAD3, it is possible that SMAD3 had the similar affinity to USP26. The authors may want to clarify it.
We thank the reviewer for pointing this out. As per the reviewers suggestion we reanalyzed the binding affinity of SMAD3 to USP26. We now demonstrate that SMAD3 appears to bind with a greater affinity to USP26 then SMAD7. We now also demonstrate this interaction endogenously. The fact that USP26 can bind to both SMAD3 and SMAD7 is not surprising. Similarly, USP15 binds to SMAD3 and SMAD7 and recently it has been documented that USP9X can deubquitinate SMURF1 and SMAD4. Indicating that a number of deubquitinating enzymes act on multiple nodes of the TGF-β pathway to effect overall TGF-β output. This point has now been further analyzed in the discussion (New Figure EV2A, B) Reviewer #2 : Fig 3 C, D 
, F, and G used overexpression of multiple plasmid to address the stability of a certain protein, which is questionable. It would be better to determine the stability of the endogenous target proteins either in the stable cell lines or in tumor cell lines.
We agree. As discussed above we now demonstrate that loss of USP26 degrades endogenous SMAD7 and stabilizes endogenous TGF-β receptor I (New Figure 3C, 3E, 3H ).
Reviewer #2: Fig 3E the actin input was not even, which made the trend of SMAD7 proteins questionable. It is also strange that the TGFβ stimulation was applied in this assay. Fig 3A and B showed a strong UB signal without TGFβ, suggesting that TGFβ stimulation is not required to trigger the degradation of SMAD7.
We thank the reviewer for their comment. We performed this original experiment in triplicate with cyclohexamide and TGF-β adhering to the methodology from other publications analyzing the stability of SMAD7. However, as per the reviewer's suggestions we now observe that USP26 knockdown destabilizes SMAD7 in the absence as well as in the presence of TGF-β. We now demonstrate that loss of USP26 enhances SMAD7 degradation in 6 independent figures and feel that in our present manuscript original figure 3E does not significantly add to our argument that loss of USP26 destabilizes SMAD7 and therefore have now excluded this figure.
Reviewer #2: Whereas USP26 knock-down upregulated the ubiquitination of SMAD7, overexpression of USP26 as a DUB to downregulate the ubiquitination of SMAD7 should be presented.
This was previously shown in our original submission Supplementary figure 2A ,B (now labeled figure EV2 E, F).
Reviewer #2: Fig 1D showed that KD of USP26 dramatically upregulated SMAD7 mRNA levels. Is it possible that in tumor cells, lack of USP26 may trigger the upregulation of SMAD7 transcription to compensate for the loss of SMAD7 proteins? The authors may want to do the immunohistochemical analysis of the tumor tissues used in Fig 4 to address the question.
As part of a negative feedback loop TGF-β directly induces the transcription of SMAD7 to downregulate TGF-β activity through degradation of the TGF-β receptor by the SMAD7:SMURF2 complex. Therefore any factor that affects TGF-β receptor stability will likely have an effect on SMAD7 transcription. So increased SMAD7 transcription is not a direct compensatory mechanism for the loss of SMAD7 proteins but rather an effect of overall activation of the TGF-β pathway through TGF-β receptor stability. Our original glioblastoma samples were purchased through BIOMAX, which unfortunately has discontinued this series of samples. To perform this experiment would require us to perform all of our IHC experiments again at great expense. Nevertheless, we believe we have clearly demonstrated that USP26 is a novel regulator of SMAD7 by showing that loss of USP26 degrades SMAD7 in glioblastoma cell lines suggesting that this would also be true in glioblastoma patient samples.
Reviewer #2: Could the authors perform a combined analysis of TGFβ and USP26 by using the REMBRANDT database to clarify the importance of USP26 in TGFβ pathway? They could compare the patient prognosis of TGFβHigh/LowUSP26High/Low groups (4 groups).
We thank the reviewer for this excellent suggestion. Unfortunately, the REMBRANDT database does not allow for multi-gene analysis. However, we analysed the role of TβRI, TβRII, TβRIII and SMAD7 expression on overall survival. In line with our previous we now demonstrate that high TβRI and TβRII expression confers poorer overall survival then patients with low TβRI and TβRII. Similarly, patients with low SMAD7 also exhibited poorer overall survival then patients with high levels of SMAD7. This is consistent with our conclusions that loss of USP26 destabilizes SMAD7 leading to stabilization TβRI and overall increased activation of the TGF-β pathway (New Figure  EV5B, C, D, E ).
Reviewer #3: Overall, the authors show some interesting results that highlight the potential role of USP26 as a de-ubiquitylase for Smad7 that controls TGF-b signaling. The data shown are convincing.
We thank the reviewer for thinking our results are convincing.
Reviewer #3: -The authors use phosphoSmad2 as read-out of TGF-b-induced Smad activation, and then look at transcription targets that are activated by Smad3. Since Smad3 is the major Smad effector for TGF-b, some data should show the effect of USP26 on Smad3 activation.
We agree. We now demonstrate that loss of USP26 also enhances SMAD3 phosphorylation. Curiously, however, SMAD3 phosphorylation was not further induced following the addition of TGF-β. (New Figure EV1 G) 
Reviewer #3: Can the authors show that USP26 associates with endogenous Smad6 or Smad7 (rather than cotransfected, overexpressed proteins)? Is this endogenous interaction ligand-induced?
We have included new data demonstrating the binding of GFP-USP26 to endogenous SMAD6 and SMAD7. Unfortunately, we were unable to identify an antibody detecting endogenous USP26. Furthermore, we identify that the binding of SMAD7 to USP26 is enhanced following TGFB. This observation was not observed for SMAD6 and USP26. (New Figures 2E, F. Figure EV2C, D We thank the reviewer for their comment. We have performed these experiments and demonstrate that that like SMURF2, SMURF1 forms a complex with SMAD7 and USP26 (New Figures EV2G).
Reviewer #3: Related to the functional link of USP26 with Smurf2-mediated ubiquitylation, what is the effect of increased or decreased USP26 expression on Smad7 levels when Smurf2 expression is downregulated? And what happens to the TbRI levels under these circumstances?
Please see the comments above.
Reviewer #3: Can the authors show that USP26 controls endogenous Smad7 levels?
Reviewer #3: Does increased or decreased USP26 expression affect the levels of Smad7, when proteasomal degradation is inhibited? This should not be the case, if the authors are right, but such data need to be shown in conjunction with Fig. 3C, D. We thank the reviewer for this excellent suggestion. We now demonstrate that the proteasome inhibitor MG132 rescues both ectopically expressed and endogenous SMAD7 levels in cells depleted for USP26. (New Figures 3D, E This has now been corrected.
Reviewer #3: Some incorrect or awkward sentences can be found. Maybe read over it one more time to further polish the text.
We have edited the text where we felt it may have been confusing and hope that the reviewer is in agreement with our changes. We thank the reviewer for their suggestion. We had hoped to further enhance our conclusions that loss of USP26 enhances TGF-β with multiple non-overlapping hairpins, thereby arguing against an off-target effect. Figure 2B has now been placed in the expanded view section as figure EV1 D.
Reviewer #3: page 7, first sentence of first full paragraph: This statement is an exaggeration.
This has now been edited.
Reviewer #3: On page 10, halfway: Mark that the Discussion starts there.
This has been corrected. Thank you for the submission of your revised manuscript to our editorial offices. As Martina Remold is currently traveling, I am handling your manuscript for the time being. We have now received the reports from the two referees that were asked to re-evaluate your study. Please find them enclosed below.
As you will see, both referees support the publication of your manuscript in EMBO reports. However, both referees have further minor comments that we ask you to address in a final revised version. After cross-commenting with referee #3, we do not think that it is necessary to repeat the experiments indicated by referee #1 using MDA-MB-231 cells (or another tumor cell line) to allow publication of the manuscript. However, in case you have such data, or can provide this in a timely manner, we would ask you to include these in the final revised manuscript.
Further, I have these editorial requests:
The figures are currently in landscape format. Please submit these as portrait. Please refer to: http://embopress.org/sites/default/files/EMBOPress_Figure_Guidelines_061115.pdf
Please provide a title and a legend for Table 1 .
Regarding data quantification and statistics, can you please specify the number "n" for how many experiments were performed, the bars and error bars (e.g. SEM, SD) and the test used to calculate pvalues in the respective figure legends? This information must be provided in the figure legends. Please provide statistical testing where applicable.
Please add scale bars to all microscopic images.
We noted that large parts of the first paragraph of the introduction are very similar to the same section of a review article you published recently (http://www.jscholaronline.org/articles/JCRTO/(de)-ubiquitination-in-the-tgf-beta-pathway.pdf). I would therefore ask you to rephrase or re-write that part of the manuscript.
We highly appreciate that you submitted the source data for the Western blots. However, could you please split these up and submit one PDF file per figure or EV figure (as these files will then later be linked to the single figures in the online version of the paper).
REFEREE REPORTS -------------------------
Referee #1:
In this revised version of the manuscript, the authors satisfactorily addressed most of the concerns and significantly improved the quality of the manuscript.
However, one additional issue should be clarified by the authors: In the new Figure 4G , as equal amount of plasmids were transfected into the cells, why is the GFP-USP26C/S band in Western bolt invisible?
In regard to the revision in addressing Reviewer #2's comments: In my opinion, the authors have satisfied most of the reviewer #2's concerns, and consequently enhanced the evidence of molecular mechanism part of the manuscript. However, one major issue, which reviewer #2 has pointed out and I was also concerned, has to be addressed before publication: a lot of functional experiments were still performed only in 293T cells in the revised manuscript, the new Figures 1C, 1E , 1G, 3C, 3E, 3G and 3H should be tested in MDA-MB-231 cells or other tumor cell lines to strengthen the conclusions.
This manuscript has been extensively revised in response to the reviewers' comments, and the comments by the reviewers 2 and 3 have been addressed, either in the rebuttal or with new data or in the revised text. I did not evaluate whether the comments of reviewer 1 were addressed. As a result, this is now a much better manuscript with a much better "story".
I have some questions and comments that are minor compared to those of the previous review. I believe that it is worth it that the authors go once more over the text to improve the writing, and, in doing so, address the comments below.
-Important for this manuscript is the statement in paragraph 2 of page 4, dealing with the relative roles of Lys48 and Lys63. For this statement the authors refer to reference 16, but I do not see that information in reference 16, which, incidentally, is a review that does not deal with TGF-b signaling. So, where does this information come from? -At several points in the Discussion, statements are made that would benefit from having a reference attached to it.
-"data" is plural. So, "this data suggests" should be "these data suggest". This is relevant for a number of sentences in the text.
-The authors exceedingly use "as expected" in their Results section, but not everything is necessarily "as expected".
-The "official" recommendation is to use "ubiquitylation" rather than "ubiquitination". This is an issue for the entire manuscript.
-The Introduction and Discussion could be shorted with 20% without loss. They tend to go on...
- Fig. 3A is not convincing to me and does not show clearly what is concluded from it. Also, that sentence (page 7, lines 4 and 3 from the bottom) is grammatically not clear.
- Fig. 3I : I am surprised that cell surface TbRI shows up as such a tight band, since it is normally glycosylated.
11. Identify the committee(s) approving the study protocol.
12. Include a statement confirming that informed consent was obtained from all subjects and that the experiments conformed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report.
13. For publication of patient photos, include a statement confirming that consent to publish was obtained.
Please ensure that the answers to the following questions are reported in the manuscript itself. We encourage you to include a specific subsection in the methods section for statistics, reagents, animal models and human subjects. the exact sample size (n) for each experimental group/condition, given as a number, not a range; a description of the sample collection allowing the reader to understand whether the samples represent technical or biological replicates (including how many animals, litters, cultures, etc.).
All proteinsamples were treated in a non biased fashion. For evulation of IHC stains a trained pathologists assesed the results in a double blind fashion.
N/A definitions of statistical methods and measures:
1. Data the data were obtained and processed according to the field's best practice and are presented to reflect the results of the experiments in an accurate and unbiased manner. figure panels include only data points, measurements or observations that can be compared to each other in a scientifically meaningful way. graphs include clearly labeled error bars for independent experiments and sample sizes. Unless justified, error bars should not be shown for technical replicates. if n< 5, the individual data points from each experiment should be plotted and any statistical test employed should be justified
Please fill out these boxes ê (Do not worry if you cannot see all your text once you press return) a specification of the experimental system investigated (eg cell line, species name). All samples were treated at the same time and processed in the manner to ensure that no bias was being observed.
N/A Yes they are applicable.
All statistical analysis of all replicates was determined -/+ standard deviation of three independent experiments. P Value was determiend by two tailed T test.
where appropriate all experiments were analysed by standard deviation of three independent experiments.
Variance between groups is statiscally significant.
